News 13.03.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin...
News 10.03.2026 Schlieren (Zurich), Switzerland, March 10, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the full year 2025, marking another year of significant growth, increased market penetration, and strategic portfolio advancements. Total group revenue reached USD...
News 05.03.2026 Guerlain has chosen Microcaps’ Perfume Pearls™ technology for its new Aqua Allegoria Perle range, bringing a new type of ethanol-free, skin-hydrating fine fragrance into one of the most prestigious collections in luxury perfumery. The collaboration shows that high-performance, sensorial ethanol-free formats have a place at the very heart of a...
News 26.02.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it has entered into an agreement with Eckert &...
News 25.02.2026 Bagsværd, Denmark and Boston, MA, US, 25 February 2026 – Novo Nordisk and Vivtex Corporation today announced a partnership to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities. Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration,...